Therapeutical aspects of cerebrovascular disease.
Treatment of hemorheologic alterations in patients with CVD must be directed to reduce enhanced platelet and red cell aggregation, to improve reduced red cell deformability, and to control plasmatic hypercoagulability.
D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation; D002561:Cerebrovascular Disorders / Q000628:therapy*; D002994:Clofibrate / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004903:Erythrocyte Aggregation; D004912:Erythrocytes / Q000187:drug effects / Q000502:physiology; D006801:Humans; D002546:Ischemic Attack, Transient / Q000517:prevention & control; D010431:Pentoxifylline / Q000494:pharmacology / Q000627:therapeutic use; D010949:Plasma / Q000502:physiology; D010974:Platelet Aggregation; D013442:Sulfinpyrazone / Q000627:therapeutic use
D004176:Dipyridamole; D002994:Clofibrate; D001241:Aspirin; D010431:Pentoxifylline; D013442:Sulfinpyrazone